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Abstract
Purpose Novel multiple myeloma (MM) therapies have in-
creased patient longevity but are often associated with notable
symptom burden. This study quantified the effect of general
symptom level, specific symptoms, and treatment-related ad-
verse events (AEs) on MM patients’ health-related quality of
life (HRQoL).
Methods The European Organization for Research and Treat-
ment of Cancer (EORTC) generic cancer questionnaire (Quality
of Life Questionnaire Core 30) and MM-specific questionnaire
(QLQ-MY20) were used in this study to assess patients’
HRQoL. Data were collected on sociodemographics, disease
and treatment history, and the presence/severity of MM-related
symptoms or treatment-related AEs from patients with MM in
11 UK and German centers. Multiple regression analyses were
conducted.
Results Of 154 patients (63 % male; mean age, 66.4 years;
mean time since diagnosis, 3.7 years; 52 % currently on treat-
ment; and 43 % with ≥1 prior MM therapy), 25, 32, 31, and
11 % were severely symptomatic, moderately symptomatic,
mildly symptomatic, and asymptomatic, respectively. Fatigue
(59 %), bone pain (51 %), sleepiness (36 %), hypoesthesia or
paresthesia (33 %), and muscle cramps (31 %) were most
commonly reported. Moderate and severe general symptom
levels, bone symptoms, depression, and mental status changes
were identified as strong determinants of HRQoL.
Conclusions Severity, type of disease symptoms, and treatment-
related AEs are important HRQoL determinants in patients with
MM, allowing for targeted treatment.
Keywords Adverse events . Health-related quality of life .
Multiple myeloma . Symptoms
Introduction
Multiple myeloma (MM) is the second most prevalent hema-
tologic malignancy, representing 1 % of all cancers, with an
increasing incidence due to population longer life expectancy
and increasing prevalence due to improved treatments [1, 2].
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According to estimates by the European Network of Cancer
Registries, there are 21,420 new cases of MM in Europe
annually and approximately 15,000 MM-related deaths. At
any time, >77,000 people in Europe are undergoing treatment
for MM [3].
Significant progress has been achieved in the treatment
of MM in recent decades [4, 5]. The use of high-dose
chemotherapy with stem cell transplantation (SCT) im-
proved disease-free survival, and has increased overall
survival (OS) compared with standard conventional che-
motherapy comprising melphalan and prednisone [6].
More recently, the introduction of novel therapeutic agents
has improved treatment response rates and progression-free
survival of patients with MM [7–16]. Improved OS has
also been reported in patients treated with thalidomide,
lenalidomide, or bortezomib [4]. However, in many cases
there is a distinct symptom burden associated with the
increased longevity and longer disease course [17, 18].
The management of patients with MM may be improved
by a better understanding of the extent to which patients
are affected by general symptom level, specific symptoms,
and treatment-related adverse events (AEs) and how this,
in turn, impacts health-related quality of life (HRQoL).
This study was conducted to quantify the effect of patients’
general symptom level on HRQoL, and to identify specific
disease-related symptoms and treatment-related AEs associat-




This cross-sectional, bi-national, multicenter study enrolled
consecutive MM patients presenting for routine care visits at
five UK and six German sites. All enrolled patients were
required to understand and voluntarily sign an informed con-
sent form. Eligible patients were aged ≥18 years with a current
diagnosis of MM and were representative of one out of four
pre-defined study subgroups: asymptomatic, mildly symp-
tomatic, moderately symptomatic, or severely symptomatic.
Each study subgroup remained open for enrollment until a
quota of 51 patients was reached.
Patients were not eligible for enrollment if they had under-
gone an autograft transplantation within the past 3 months or
if they had received an experimental MM treatment.
The study was approved by the institutional review boards
of the participating Centres and conducted according to the
Declaration of Helsinki International Conference on Harmo-
nization and the guidelines for Good Clinical Practice.Written
informed consent was obtained from all patients before
enrollment.
Instruments
The European Organization for Research and Treatment of
Cancer (EORTC) Quality of Life Questionnaire Core 30
(QLQ-C30) and MM module questionnaire (QLQ-MY20)
were used to measure patients’ HRQoL. These questionnaires
have been shown to be reliable and valid measures for
detecting differences in the quality of life (QoL) of patients
with cancer and specifically in those with MM [19–21].
Differences of 6–17 points in selected scores of the EORTC
QLQ-C30 have been found to represent a clinically meaning-
ful change in patients withMM, whereby a 10-point reduction
can be interpreted as amoderate effect size [22]. A preliminary
study by Williams et al. [23] demonstrated that Physical
Functioning, Social Functioning, and Fatigue from QLQ-
C30; and Future Perspective and Disease Symptoms from
QLQ-MY20 are important determinants of Global Health
Status/QoL. These subscales were, therefore, the main focus
of this paper.
Patients’ general symptom level
Each patient’s general symptom level was determined using
an MM symptoms and AE checklist and classification form.
This form was developed in English by five hematologists
(Drs Hall, Crotty, Oakervee, Che, and Ashcroft), all experi-
enced in treating patients with MM, and then translated into
German and administered by the physician during treatment.
Patients with MM were asked to provide a score from 1 to 4
for each of 39 MM symptoms/AEs pre-defined as clinically
relevant. The list of symptoms/AEs included bone pain, frac-
ture, fatigue, and motor and sensory neuropathy. Final AE
severity categories were assigned based on the average score
for each grade of symptom/AE. Based on the severity of the
reported AEs and symptoms, patients were assigned to one of
four symptom groups: asymptomatic if a patient had no
symptoms/AEs; mildly symptomatic if a patient reported ≥1
mild symptom/AE and no moderate or severe symptom/AE;
moderately symptomatic if a patient reported ≥1 moderate
symptom/AE and no severe symptoms/AEs; and severely
symptomatic if a patient reported ≥1 severe symptom/AE.
Data collection
Data on HRQoL (EORTC QLQ-C30 and EORTC QLQ-
MY20) were also collected at a single patient study visit.
The QLQ-C30 comprises a Global Health Status/QoL do-
main, five functional and three symptom domains, and six
AE items. The QLQ-MY20 includes scales for Disease Symp-
toms, Side Effects of Treatment, Future Perspective, and Body
Image. Values for each scale range from 0 to 100. Higher
values indicate better HRQoL for the Global Health Status/
QoL, Functional, Future Perspective, and Body Image scales.
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By contrast, higher values indicated a worse HRQoL score for
the AE items, symptom domains, Disease Symptoms, and AE
scales. Scoring of the QLQ-C30 [24] and QLQ-MY20 [21]
scales has been described previously.
The site study staff completed a sociodemographics form
and a medical history form based on each participant’s medical
record. The sociodemographics form included information
about age, gender, and nationality of the patients, whereas the
medical history form contained data on height, weight, date of
MMdiagnosis, laboratory tests, presence of lytic bone lesion or
pathological fracture at the time of diagnosis, comorbidities,
and SCT/MM treatment history. Each line of treatment was
classified as containing bortezomib, lenalidomide, thalidomide,
alkylating agents, or “other treatments.” Current treatment was
defined as the regimen received within 30 days of the study
visit. Prior treatment was defined as the MM regimen received
within the past 12 months and preceding the study visit by
>30 days.
Statistical analysis
The associations between symptom level plus individual
symptoms/AEs on the one hand and Global Health Status/
QoL, Physical Functioning, Social Functioning, Fatigue, Dis-
ease Symptoms, and Future Perspective as dependent outcome
variables on the other hand were explored via multiple linear
regression analyses. The majority of the symptoms/AEs col-
lected in the study were reported rarely and, as a consequence,
different severity levels of AEs included only a few patients.
Thus, to allow meaningful analysis, only the presence or ab-
sence of the rarely reported symptoms/AEs were considered.
In addition to symptom level and individual symptoms/AEs
and their severity, the following variables were considered for
the multiple regression analysis: age, gender, nationality, body
mass index, duration of disease, beta-2-microglobulin and al-
bumin levels at diagnosis, lytic bone lesion or pathological
fracture at diagnosis, number of comorbidities present at the
study visit, prior SCT, type and duration of current/prior treat-
ment, number of prior treatments, interaction between type and
duration of current/prior treatment, response to last cycle of
current treatment, and best response to last cycle of (all) prior
treatment(s) combined.
Given the number of potential predictors of interest and
patient sample size (N=154), multiple regression models were
constructed giving priority to symptom severity group and indi-
vidual AEs. The following strategy was used to prioritize vari-
ables of interest: each of the 39 specific AEs was tested in
univariate regression models against the six HRQoL measures;
those that were statistically significant (P<0.10) were then tested
in a model including the general symptom level. Those found to
be significant in this second stepwere combined in amultivariate
model that was then trimmed to exclude items that lost signifi-
cance. Other potential determinants, like sociodemographics and
disease and treatment history variables, found to be significant in
univariate analyses were then added to the trimmed multivariate
model, which was further reduced by excluding nonsignificant
terms.
Results
Patients disposition and characteristics
The study enrolled 154 patients (89 and 65 patients from the
UK and Germany, respectively). A total of 39 (25 %) patients
enrolled in the study were severely symptomatic, 50 (32 %)
were moderately symptomatic, 48 (31 %) were mildly symp-
tomatic, and 17 (11 %) were asymptomatic. Average age at
enrollment was 66.4 years (interquartile range (IQR), 61.0–
74.0) and 63 % were male. The majority of patients (84 %)
were of British or German descent. The average time since
diagnosis was 3.7 years (IQR, 0.9–5.7). Patients in more
severe symptom groups showed a trend towards a higher
number of comorbidities (Table 1) and were more likely to
be on a current MM regimen (Table 2).
Symptoms
The most commonly reported AEs included fatigue (59 %),
bone pain (51 %), sleepiness (36 %), hypoesthesia or pares-
thesia (33 %), muscle cramps (31 %), constipation (28 %),
peripheral edema (26 %), and insomnia (25 %). Dizziness
(19 %), blurred vision (19 %), dehydration or thirstiness
(18 %), infection (16 %), tremor (15 %), sensory (painful)
neuropathy (15 %), headache (14 %), depression (14 %), and
nausea/vomiting (12 %) were reported less frequently. Other
AEs and disease symptoms were reported by <10 % of pa-
tients (Fig. 1).
Treatment history
Overall, 80 patients (52 %) were on treatment in the month
prior to the study visit. Of these, 37 (46 %) patients received
regimens based on bortezomib, 17 (21 %) patients received
lenalidomide-containing regimens, 15 (19 %) patients had
treatments based on thalidomide, 8 (10 %) patients received
alkylating agents, and 3 (4 %) patients had other types of
treatment. More than half of all patients (57 %) had no prior
treatment, 32 % had received 1 prior treatment in the past
12 months, and the remaining 11 % had received ≥2 prior
therapies within 12 months of the study visit (Table 2).
HRQoL by general symptom severity level
The overall mean±standard deviation Global Health Status/
QoL score was 60.1±25.5, with the IQR between 41.7 and
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83.3. Physical Functioning (mean, 68.7; IQR, 53.3–93.3) and
Social Functioning (mean, 63.9; IQR, 33.3–100) scores were
slightly higher than Future Perspective scores (mean, 59.9;
IQR, 33.3–77.8). Higher symptom severity levels were associ-
ated with greater impairments in HRQoL; ≥6-point difference
in average score between each level was observed for Global
Health Status/QoL, Physical Functioning, and Social Function-
ing (Fig. 2). The reported mean score for Future Perspective
was nearly 20 points higher for asymptomatic and mildly
symptomatic patients, compared with patients in the moderate-
ly and severely symptomatic groups. Fatigue scores were
highest among patients in the severely symptomatic group














Currently (past 30 days) receiving MM therapy (n (%)) 80 (52) 7 (41) 19 (40) 33 (66) 21 (54)
Type of current MM therapy (n (%))
Bortezomib containing 37 (46) 3 (43) 7 (37) 19 (58) 8 (38)
Lenalidomide containing 17 (21) 3 (43) 4 (21) 6 (18) 4 (19)
Thalidomide containing 15 (19) 1 (14) 6 (32) 4 (12) 4 (19)
Alkylating agents containing 8 (10) 0 2 (11) 4 (12) 2 (10)
Other 3 (4) 0 0 0 3 (14)
Number of prior MM therapies in the past 12 months (n (%))
0 88 (57) 11 (65) 29 (60) 28 (56) 20 (51)
1 49 (32) 3 (18) 15 (31) 18 (36) 13 (33)
2 13 (8) 3 (18) 3 (6) 3 (6) 4 (10)
≥3 4 (3) 0 1 (2) 1 (2) 2 (5)
Type of prior MM therapy in the past 12 months (n (%))
Bortezomib containing 28 (18) 5 (29) 4 (8) 9 (18) 10 (26)
Lenalidomide containing 3 (2) 0 1 (2) 2 (4) 0
Thalidomide containing 31 (20) 2 (12) 12 (25) 9 (18) 8 (21)
Alkylating agents containing 17 (11) 2 (12) 5 (10) 5 (10) 5 (13)
Other 6 (4) 0 2 (4) 1 (2) 3 (8)
MM multiple myeloma











Male (n (%)) 97 (63) 12 (71) 31 (65) 27 (54) 27 (69)
Age (mean±SD, years) 66.4±10.0 66.9±11.0 66.0±8.9 67.4±10.3 65.5±10.8
Nationality (n (%))
British 73 (47) 5 (29) 27 (56) 29 (58) 12 (31)
German 56 (36) 12 (71) 11 (23) 15 (30) 18 (46)
Other 25 (16) 0 10 (21) 6 (12) 9 (23)
Comorbidities present at the time of the visit (n (%))
None 49 (32) 6 (35) 17 (35) 19 (38) 7 (18)
1 44 (29) 6 (35) 15 (31) 17 (34) 6 (15)
2 24 (16) 5 (29) 6 (13) 5 (10) 8 (21)
≥3 37 (24) 0 10 (21) 9 (18) 18 (46)
Duration of MM (mean±SD, years) 3.7±3.7 3.3±3.3 3.6±3.9 4.2±3.7 3.6±3.4
MM multiple myeloma, SD standard deviation
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(mean, 58.1; IQR 44.4–77.8), whereas patients in the asymp-
tomatic group had a mean of 15.7 (IQR, 0–33.3) (Fig. 3).
Results of multiple regression analyses
Global Health Status/QoL
Patients with severe and moderate symptoms had on aver-
age 19 and 12 points lower QoL scores, respectively,
compared with asymptomatic patients. Patients with severe
bone pain had an additional 21-point reduction in score
compared with those who had none or only mild or mod-
erate bone pain. Depression and moderate fatigue had
similar effects on Global Health Status/QoL scores and
each was associated with an 11-point reduction in score.
Each additional year with MM was associated with a QoL
reduction of 1 score point. Receiving any type of MM
treatment within the past 30 days was also associated with
a 9.5-point reduction in the Global Health Status/QoL
score (Table 3).
Fig. 1 Frequently reported
multiple myeloma symptoms and
adverse events. Collapse of
vertebral body, bone fracture,
abdominal pain, petechiae/
purpura, gastrointestinal bleeding,
upper respiratory tract infection,
pneumonia, fever, febrile
neutropenia, diarrhea, asthenia or
tiredness, anorexia, dyspepsia,
motor neuropathy, carpal tunnel
syndrome, syncope, states of
confusion, mental status changes,
cerebrovascular accident, rash,
deep-vein thrombosis,
hypotension, and renal failure
were reported by <10 % of
patients
Fig. 2 Distribution of health-
related quality of life by symptom
level: Global Health Status/
Quality of Life (QoL), Physical
Functioning, Social Functioning,
and Future Perspective. Higher
scores are “better”; error bars
represent standard deviation
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Physical functioning
General severity level was a strong predictor of Physical Func-
tioning; patients with severe, moderate, and mild symptom
levels (vs. none) experienced a 24-, 13- and 11-point reduction
in their Physical Functioning score, respectively. In addition to
the overall level of severe andmoderate bone pain, the presence
of fracture, moderate fatigue, and moderate/severe infection
were all associated with ≥10-point decrease in Physical Func-
tioning score. Longer prior treatment with bortezomib also
reduced Physical Functioning levels. Patients who were treated
with bortezomib-containing regimens for 111 days (approxi-
mately 5.5 cycles of 21-days) had on average a 10-point lower
Physical Functioning score compared with patients who had
not received prior bortezomib. Thalidomide and alkylating
agent-containing treatments had no significant effect on Phys-
ical Functioning. Prior lenalidomide and prior other treatments
were not tried in the regression analyses because of the low
number of patients with a history of these treatments (3 and 6,
respectively). British and younger patients tended to report
better Physical Functioning (Table 3).
Social functioning
Social Functioning was significantly affected by general
symptom level. Patients with severe, moderate, and mild
symptoms had Social Functioning scores that were on average
34, 24, and 6 points lower, respectively, compared with
asymptomatic patients. Fracture, dizziness, and changes in
mental status were also associated with a significant reduction
in the Social Functioning score (Table 3).
Fatigue
Both severe bone pain and fatigue had a strong association with
patient Fatigue score; an average increase of approximately 22
points in the Fatigue score was observed in patients with severe
bone pain and those with moderate fatigue. Dizziness, sleepi-
ness, nausea and/or vomiting, and a higher number of
comorbidities were also associated with increased fatigue level.
Patients whose current treatment regimen contained
bortezomib, lenalidomide, or alkylating agents/other treatments
reported, on average, an increase of ≥10 points in their Fatigue
score compared with patients not receiving treatment. General
symptom level had no effect on the Fatigue score after individ-
ual AEs were included in the model (Table 3).
Disease symptoms
Patients with severe and moderate bone pain reported on
average 38- and 18-point higher Disease Symptoms scores,
respectively, compared with patients with mild or no bone
pain. Muscle cramps were associated with an 11-point in-
crease in Disease Symptoms score. Longer duration of current
treatment and being male were associated with an increase in
the Disease Symptoms score (Table 4). General symptom
level had no effect on the Disease Symptoms score once
individual AEs were included in the model.
Future perspective
Depressionwas associatedwith a 20-point reduction in the Future
Perspective score. In addition, headache, sleepiness, German
Fig. 3 Distribution of health-
related quality of life by symptom
level: Fatigue and Disease
Symptoms. Lower scores are
“better”; error bars represent
standard deviation
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descent, and receiving bortezomib- or lenalidomide-containing
treatments (compared with no treatment) were all associ-
ated with ≥10-point reduction in patients’ Future Perspec-
tive scores. General symptom level had no effect on the
Future Perspective score after depression, headache, and
sleepiness were included in the model (Table 4).
Discussion
Our study demonstrates that both severity and type of disease
symptoms, and treatment-related AEs are important determi-
nants of HRQoL in patients with MM. Higher disease- and
treatment-related symptom levels were associated with a low-
er Global Health Status/QoL and decreased Physical and
Social Functioning. For patients with moderate and severe
general symptoms, a reduction of 12 and 19 points in Global
Health Status/QoL, 14 and 24 points in Physical Functioning,
and 24 and 34 points in Social Functioning, respectively, were
observed. In addition, we found that specific symptoms/AEs
can impact patients’ HRQoL above and beyond their general
symptom level. Fatiguewas one such symptom/AE associated
with reduced Global Health Status/QoL and Physical Func-
tioning, a finding that is in accordance with the limited data
currently available on HRQoL in patients with MM [25].
Bone-related symptoms (i.e., pain and fracture) were also
Table 3 Results of the multiple regression analyses: EORTC QLQ-C30 subscales (95 % confidence interval)
Parameter Global Health
Status/QoL
Physical Functioning Social Functioning Fatigue
Symptom group
Mildly symptomatic vs. asymptomatic −8.04 (−19.42; 3.35) −11.44 (−22.59; −0.29)* −6.47 (−22.46; 9.51) NS
Moderately symptomatic vs. asymptomatic −11.66 (−23.93; 0.60) −13.47 (−25.79; −1.16)* −23.77 (−40.05; −7.50)* NS
Severely symptomatic vs. asymptomatic −19.11 (−32.43; −5.79)* −23.68 (−37.30; −10.06)* −33.95 (−51.10; −16.80)* NS
Bone pain
Moderate vs. mild/none NAb −10.50 (−20.04; −0.95)* NS NAb
Severe vs. mild/none NAb −18.37 (−32.26; −4.48)* NS NAb
Severe vs. moderate/mild/none −21.32 (−34.69; −7.95)* NA NS 22.62 (10.27; 34.98)*
Bone fracture: yes vs. no NS −14.53 (−25.87; −3.20)* −15.06 (−31.41; 1.28) NS
Fatigue (moderate vs. none/mild) −10.95 (−19.64; −2.25)* −14.00 (−22.52; −5.49)* NS 21.92 (13.14; 30.70)*
Infection (moderate/severe vs. mild/none) NS −21.54 (−35.52; −7.55)* NS NS
Dizziness (yes vs. no) NS NS −15.13 (−27.40; −2.86)* 11.75 (1.99; 21.51)*
Depression (yes vs. no) −10.87 (−20.65; −1.09)* NS NS NS
Mental status changes (yes vs. no) NS NS −21.83 (−45.50; 1.84) NS
Nausea/vomiting NS NS NS 14.91 (3.64; 26.18)*
Sleepiness (yes vs. no) NS NS NS 9.51 (1.43; 17.59)*
MM disease duration −0.95 (−1.85; −0.05)* NS NS NS
British descent NS 8.25 (1.61; 14.89)* NS NS
Age NS −0.50 (−0.82; −0.18)* NS NS
Number of comorbidities NS NS NS 2.55 (0.36; 4.73)*
Prior bortezomiba treatment duration NS −0.09 (−0.14; −0.04)* NS NS
Currently on treatment (yes vs. no) −9.49 (−16.16; −2.83)* NS NS NS
Type of current treatment
Bortezomib containing vs. none NS NS NS 10.56 (1.80; 19.33)*
Lenalidomide containing vs. none NS NS NS 14.56 (2.78; 26.34)*
Thalidomide containing vs. none NS NS NS 3.93 (−8.66; 16.52)
Alkylating agents containing/other vs. none NS NS NS 10.74 (−3.23; 24.71)
MM multiple myeloma, QoL quality of life, NS not significant at 0.1 level (i.e., P value of >0.1), NA not applicable
*P value of <0.05
a Prior thalidomide or alkylating agents were nonsignificant; prior lenalidomide and other treatments were not tested due to very low sample size (n =3
and n =6, respectively)
b For Global Health Status and Fatigue, severity of bone pain was grouped into severe vs. moderate/mild/none given that there were no statistically
significant differences between moderate, mild, and no bone pain on these scales. For Physical Functioning, severity of bone pain was grouped into severe,
moderate, and mild/none given that there were no statitistically significant differences in effect on physical functioning between mild and no bone pain
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important determinants that affected Global Health Status/
QoL, Physical and Social Functioning, Fatigue, and Disease
Symptoms beyond general symptom levels. A previous study
reported that in patients with certain types of malignancies,
including myeloma, pathologic fractures correlate with re-
duced survival [26]. Depression was found to have a very
strong negative association with the Future Perspective score.
Moreover, mental status changes were associated with a re-
duction of almost 22 points in Social Functioning score.
Similar findings have been reported in other studies [27, 28].
To our knowledge, this is the first study to assess the
impact of general severity level of disease symptoms/AEs
on patients’ HRQoL and to examine whether specific
symptoms/AEs affect the HRQoL of patients with MM more
than others. The findings provide an insight for clinicians on
how to better treat patients with MM to improve their QoL.
These data underscore the need to better manage the treat-
ment of symptoms associated with fatigue and bone-related
symptoms because these are the strongest predictors of
HRQoL. Our study also suggests that certain aspects of
QoL such as Future Perspective, Disease Symptoms, and
Fatigue can be improved significantly by targeted treatment
of specific symptoms/AEs. Better psychological support
aimed at preventing depression and other mental status
changes can also greatly improve social functioning and
patients’ perception of the future, while better prevention
of bone pain, nausea/vomiting, dizziness, and sleepiness can
reduce fatigue levels in patients with MM.
Cancer patients experience a multitude of symptoms as a
result of their disease and/or the treatments they receive. These
symptoms often appear in clusters, which may suggest a
common underlying cause. For example, the symptom cluster
pain, fatigue, and sleep disorder is well established [29]. It has
been shown that undertreated pain interrupts nighttime sleep
but adequate pain control can reduce sleep problems [30].
Furthermore, fatigue intensity is strongly correlated with the
efficiency of sleep and total sleep time [31]. This concept of
symptom clustering underlines the importance of treating
specific symptoms, such as pain, to improve the general
symptom of global fatigue. Results from this study also high-
light the need for the treating physicians to consider the
overall sum of an MM therapy’s clinical efficacy, its toxicity
profile, and its effect on QoL when selecting an appropriate
treatment strategy.
Our study does have some limitations. Treatment of any
type was primarily expected to negatively affect HRQoL
through related disease symptoms and AEs, with patients
requiring treatment having more severe disease [31]. Howev-
er, treatment remained a significant predictor in regression
models for Physical Functioning, Fatigue, Disease Symptoms,
and Future Perspective scales even after adjusting for disease
symptoms and AEs. This suggests that some AEs/symptoms
may have been underreported, leading to residual confound-
ing in the effect of treatment on HRQoL. As an example,
clinical evaluation has shown that as many as 75% of patients
with MMmay experience treatment-emergent peripheral neu-
ropathy [32], whereas only 25 % of patients reported it in our
study. Another possibility relating to the significance of indi-
vidual prior or current treatment variables (in the form of
treatment status or type of treatment) is that these may have
captured the effect of a multitude of AEs that, individually,
were not significant in the multiple regression analyses. Given
our limited sample size and rare reporting of some symptoms/
AEs, our analyses may have been underpowered to detect
additional and potentially important symptoms/AEs, or addi-
tional groups of symptoms/AEs that impact patients’HRQoL.
Table 4 Results of the multiple
regression analyses:
EORTC QLQ-MY20 subscales
with (95 % confidence interval)
NS not significant at 0.1 level
(i.e., P value of >0.1), NA not
applicable
*P value of <0.05
Parameter Disease Symptoms Future Perspective
Bone pain
Moderate vs. mild/none 18.08 (10.77; 25.38)* NS
Severe vs. mild/none 37.54 (27.77; 47.31)* NS
Depression (yes vs. no) NS −20.11 (−32.31; −7.92)*
Sleepiness (yes vs. no) NS −13.32 (−22.14; −4.50)*
Muscle cramps (mild/moderate vs. none) 10.80 (−0.71; 22.32) NS
Headache (yes vs. no) NS −13.25 (−24.93; −1.57)*
German descent NS −11.82 (−20.40; −3.23)*
Sex (female vs. male) 9.63 (3.85; 15.41)* NS
Type of current treatment
Bortezomib containing vs. none NS −10.13 (−20.30; 0.04)
Lenalidomide containing vs. none NS −11.63 (−25.10; 1.85)
Thalidomide containing vs. none NS 0.64 (−13.57; 14.85)
Alkylating agents containing/other vs. none NS −6.33 (−22.50; 9.85)
Duration of current treatment 0.02 (0.00; 0.03) NS
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Conclusions
This study showed that, in addition to specific symptoms/AEs,
the overall severity level is also an important predictor of
patients’ HRQoL. New treatment strategies should, therefore,
focus not only on improving disease control and prolong sur-
vival but also contribute to optimal symptom management to
improve, or at least maintain, patient QoL. Further studies
should evaluate whether a specific, patient-focused symptom
management program can positively affect QoL in patients
receiving newMM treatment regimens. In addition, the assess-
ment of the relationship between pretreatment disease status
and treatment-emergent AEs is necessary to determine whether
certain types of AE are associated with different Eastern Co-
operative Oncology Group (ECOG) performance status.
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